Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-07-05
2011-07-05
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S141100, C424S145100
Reexamination Certificate
active
07972597
ABSTRACT:
The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
REFERENCES:
patent: 6084075 (2000-07-01), Lind et al.
patent: 2007/0134236 (2007-06-01), De Fougerolles et al.
patent: 09067399 (1997-03-01), None
patent: WO 95/09232 (1995-04-01), None
patent: WO-97/31949 (1997-09-01), None
patent: WO-00/05265 (2000-02-01), None
patent: WO-01/57226 (2001-08-01), None
Beers and Berkow. (1999). The Merck Manual of Diagnosis and Therapy, 17 th edition, pp. 1474-1476.
Jee, Youngheun et al., “Upregulation of monocyte chemomatic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats,”Journal of Neuroimmunology, 128 (2002) 49-57.
Van Coillie et al. “The MCP/eotaxin Subfamily of CC Chemokines”Cytokine&Growth Factor Reviews, 10: 61-86 (1999).
Anonymous: “Antibodies to Cytokines & Cytokine Receptors,” Downloaded from the internet Mar. 12, 2007, according to the European Patent Office.
Boring et al. “Decreased Lesion formation in CCR2-/-Mice Reveals a Role for Chemokines in the Initiation of Atherosclerosis.”Nature394(6696): 894-897 (1998).
Callard and Gearing (1994) The Cytokine Factsbook, Academic Pres Limited, pp. 171-173.
Campbell et al. “Monocyte Chemoattractant Protein 1 Mediates Cockroach Allergen-Induced Bronchial Hyperreactivity in Normal but not CCR2-/-Mice: the Role of Mast Cells.”The Journal of Immunology, 163(4): 2160-2167 (1999).
Dean, “Preparation and Characterization of Monoclonal Antibodies to Proteins and Other Cellular Components,”Methods in Molecular Biology, vol. 32:Basic Protein and Peptide Protocols(1994).
European Supplemental Search Report of Application No. EP 03 79 0088, mailed on May 3, 2006.
European Supplemental Search Report of Application No. EP 02 792 310.1, dated Dec. 20, 2007.
Huang et al. “Absence of Monocyte Chemoattractant Protein 1 in Mice Leads to Decreased Local Macrophage Recruitment and Antigen-Specific T Helper Cell Type 1 Immune Response in Experimental Autoimmune Encephalomyelitis”Journal of Experimental Medicine, 193(6): 713-725 (2001).
International Search Report of International Application No. PCT/US02/38229, mailed on Jul. 11, 2003.
International Search Report of International Application No. PCT/US03/37834, mailed on Jul. 23, 2004.
Lummus et al. “Diisocyanate Antigen-enhanced Production of Monocyte Chemoattractant Protein-1, IL-8, and Tumor Necrosis Factor-a by Peripheral Mononuclear Cells of Workers with Occupational Asthma,”Journal of Allergy and Clinic Immunology, vol. 102(2):265-274, Aug. 1998.
Luo et al. “Serologic Analysis of the Mouse Beta Chemokine JE/Monocyte Chemoattractant Protein-1”Journal of Immunology, 153(8): 3708-3716 (1994).
Proost et al. “Human Monocyte Chemotactic Proteins 2 and 3: Structural and Functional Comparison with MCP-1.”Journal of Leukocyte Biology, 59(1): 67-74 (1996).
Salcedo et al. “Human Endothelial Cells Express CCR2 and respond to MCP-1: Direct Role of MCP-1 in Angiogenesis and Tumor Progression.”Blood, 96(1): 34-40 (2000).
Sawyer et al. “Methodology for Selection of Human Antibodies to Membrane Proteins from a Phage-Display Library,”Journal of Immunological Methods204:193-203 (1997).
Van Collie et al. “The MCP/eotaxin Subfamily of CC Chemokines”Cytokine&Growth Factor Reviews, 10:61-86 (1999).
Weber et al. “Expression of CCR2 by Endothelial Cells: Implications for MCP-1 Mediated Wound Injury Repair and in Vivo Inflammatory Activation of Endothelium.”Arteriosclerosis Thrombosis and Vascular Biology, 19: 2085-2093 (1999).
De Fougerolles Antonin R.
Garber Ellen
Kotelianski Victor E.
Reid Carl
Biogen Idec MA Inc.
Finnegan Henderson Farabow Garrett & Dunner LLP
Mertz Prema
LandOfFree
Methods of reducing chemotaxis using antibodies against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing chemotaxis using antibodies against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing chemotaxis using antibodies against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2676856